Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

• Status: Completed
• Trial end date: 2019-01-30
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LG Chem
• Treatments: Ezetimibe; Rosuvastatin Calcium; Valsartan

Criteria

Inclusion Criteria:

• Healthy male

• Age between 19 and 50

• Subjects with BMI of 18~27 kg/m2 with a weight of 55kg or more

• Subjects with SBP of 90~150 mmHg and DBP of 60~150 mmHg

• Signed informed consent

Exclusion Criteria:

• Presence of medical history or a concurrent disease

• Has a history of hypersensitivity to IP ingredients